Global RNAi Therapeutics Market Growth (Status and Outlook) 2026-2032
The global RNAi Therapeutics market size is predicted to grow from US$ 944 million in 2025 to US$ 3164 million in 2032; it is expected to grow at a CAGR of 19.6% from 2026 to 2032.
RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.
Upstream inputs include oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics. Manufacturing relies on specialized oligo synthesis, purification, and formulation under GMP. Downstream, RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization. End markets span metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders, with hospitals and specialty clinics as primary channels.
Gross margins for RNAi therapeutics are structurally attractive but heterogeneous. Commercialized siRNA drugs can achieve ~70?85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity. Margin headwinds include high COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP. Early-stage programs show lower effective margins due to small batch sizes and high quality control intensity, while mature assets benefit from learning curves and supplier consolidation.
LPI (LP Information)' newest research report, the ?RNAi Therapeutics Industry Forecast? looks at past sales and reviews total world RNAi Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected RNAi Therapeutics sales for 2026 through 2032. With RNAi Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global RNAi Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNAi Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global RNAi Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.
Upstream inputs include oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics. Manufacturing relies on specialized oligo synthesis, purification, and formulation under GMP. Downstream, RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization. End markets span metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders, with hospitals and specialty clinics as primary channels.
Gross margins for RNAi therapeutics are structurally attractive but heterogeneous. Commercialized siRNA drugs can achieve ~70?85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity. Margin headwinds include high COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP. Early-stage programs show lower effective margins due to small batch sizes and high quality control intensity, while mature assets benefit from learning curves and supplier consolidation.
LPI (LP Information)' newest research report, the ?RNAi Therapeutics Industry Forecast? looks at past sales and reviews total world RNAi Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected RNAi Therapeutics sales for 2026 through 2032. With RNAi Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global RNAi Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNAi Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global RNAi Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Subcutaneous Injection
- Intravenous Infusion
- Synthetic siRNA
- shRNA / ddRNAi
- miRNA Mimics / Inhibitors
- bi-shRNA / bifunctional RNAi
- Self-delivering RNAi
- Fully Integrated Biopharma
- Platform-driven Licensing Model
- Co-development / Profit-sharing Model
- Others
- Cardiovascular Disease
- Genetic Disorder
- Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- Phio Pharmaceuticals
- RXi Pharmaceuticals
- Arrakis Therapeutics
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
- Silexion Therapeutics
- Novartis
- Novo Nordisk
- Roche
- Sanofi
- Regeneron Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNAi Therapeutics Market Size (2021-2032)
2.1.2 RNAi Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNAi Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 RNAi Therapeutics Segment by Type
2.2.1 Subcutaneous Injection
2.2.2 Intravenous Infusion
2.2.3 RNAi Therapeutics Market Size by Type
2.2.3.1 RNAi Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global RNAi Therapeutics Market Size Market Share by Type (2021-2026)
2.3 RNAi Therapeutics Segment by Molecular Modality
2.3.1 Synthetic siRNA
2.3.2 shRNA / ddRNAi
2.3.3 miRNA Mimics / Inhibitors
2.3.4 bi-shRNA / bifunctional RNAi
2.3.5 Self-delivering RNAi
2.3.6 RNAi Therapeutics Market Size by Molecular Modality
2.3.6.1 RNAi Therapeutics Market Size CAGR by Molecular Modality (2021 VS 2025 VS 2032)
2.3.6.2 Global RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2026)
2.4 RNAi Therapeutics Segment by Business Model
2.4.1 Fully Integrated Biopharma
2.4.2 Platform-driven Licensing Model
2.4.3 Co-development / Profit-sharing Model
2.4.4 Others
2.4.5 RNAi Therapeutics Market Size by Business Model
2.4.5.1 RNAi Therapeutics Market Size CAGR by Business Model (2021 VS 2025 VS 2032)
2.4.5.2 Global RNAi Therapeutics Market Size Market Share by Business Model (2021-2026)
2.5 RNAi Therapeutics Segment by Application
2.5.1 Cardiovascular Disease
2.5.2 Genetic Disorder
2.5.3 Cancer
2.5.4 Other
2.5.5 RNAi Therapeutics Market Size by Application
2.5.5.1 RNAi Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global RNAi Therapeutics Market Size Market Share by Application (2021-2026)
3 RNAI THERAPEUTICS MARKET SIZE BY PLAYER
3.1 RNAi Therapeutics Market Size Market Share by Player
3.1.1 Global RNAi Therapeutics Revenue by Player (2021-2026)
3.1.2 Global RNAi Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global RNAi Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNAI THERAPEUTICS BY REGION
4.1 RNAi Therapeutics Market Size by Region (2021-2026)
4.2 Global RNAi Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNAi Therapeutics Market Size Growth (2021-2026)
4.4 APAC RNAi Therapeutics Market Size Growth (2021-2026)
4.5 Europe RNAi Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa RNAi Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNAi Therapeutics Market Size by Country (2021-2026)
5.2 Americas RNAi Therapeutics Market Size by Type (2021-2026)
5.3 Americas RNAi Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNAi Therapeutics Market Size by Region (2021-2026)
6.2 APAC RNAi Therapeutics Market Size by Type (2021-2026)
6.3 APAC RNAi Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNAi Therapeutics Market Size by Country (2021-2026)
7.2 Europe RNAi Therapeutics Market Size by Type (2021-2026)
7.3 Europe RNAi Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNAi Therapeutics by Region (2021-2026)
8.2 Middle East & Africa RNAi Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa RNAi Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNAI THERAPEUTICS MARKET FORECAST
10.1 Global RNAi Therapeutics Forecast by Region (2027-2032)
10.1.1 Global RNAi Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas RNAi Therapeutics Forecast
10.1.3 APAC RNAi Therapeutics Forecast
10.1.4 Europe RNAi Therapeutics Forecast
10.1.5 Middle East & Africa RNAi Therapeutics Forecast
10.2 Americas RNAi Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market RNAi Therapeutics Forecast
10.2.2 Canada Market RNAi Therapeutics Forecast
10.2.3 Mexico Market RNAi Therapeutics Forecast
10.2.4 Brazil Market RNAi Therapeutics Forecast
10.3 APAC RNAi Therapeutics Forecast by Region (2027-2032)
10.3.1 China RNAi Therapeutics Market Forecast
10.3.2 Japan Market RNAi Therapeutics Forecast
10.3.3 Korea Market RNAi Therapeutics Forecast
10.3.4 Southeast Asia Market RNAi Therapeutics Forecast
10.3.5 India Market RNAi Therapeutics Forecast
10.3.6 Australia Market RNAi Therapeutics Forecast
10.4 Europe RNAi Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market RNAi Therapeutics Forecast
10.4.2 France Market RNAi Therapeutics Forecast
10.4.3 UK Market RNAi Therapeutics Forecast
10.4.4 Italy Market RNAi Therapeutics Forecast
10.4.5 Russia Market RNAi Therapeutics Forecast
10.5 Middle East & Africa RNAi Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market RNAi Therapeutics Forecast
10.5.2 South Africa Market RNAi Therapeutics Forecast
10.5.3 Israel Market RNAi Therapeutics Forecast
10.5.4 Turkey Market RNAi Therapeutics Forecast
10.6 Global RNAi Therapeutics Forecast by Type (2027-2032)
10.7 Global RNAi Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNAi Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Information
11.1.2 Alnylam Pharmaceuticals RNAi Therapeutics Product Offered
11.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Alnylam Pharmaceuticals Main Business Overview
11.1.5 Alnylam Pharmaceuticals Latest Developments
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Company Information
11.2.2 Arrowhead Pharmaceuticals RNAi Therapeutics Product Offered
11.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Arrowhead Pharmaceuticals Main Business Overview
11.2.5 Arrowhead Pharmaceuticals Latest Developments
11.3 Silence Therapeutics
11.3.1 Silence Therapeutics Company Information
11.3.2 Silence Therapeutics RNAi Therapeutics Product Offered
11.3.3 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Silence Therapeutics Main Business Overview
11.3.5 Silence Therapeutics Latest Developments
11.4 Benitec Biopharma
11.4.1 Benitec Biopharma Company Information
11.4.2 Benitec Biopharma RNAi Therapeutics Product Offered
11.4.3 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Benitec Biopharma Main Business Overview
11.4.5 Benitec Biopharma Latest Developments
11.5 Phio Pharmaceuticals
11.5.1 Phio Pharmaceuticals Company Information
11.5.2 Phio Pharmaceuticals RNAi Therapeutics Product Offered
11.5.3 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Phio Pharmaceuticals Main Business Overview
11.5.5 Phio Pharmaceuticals Latest Developments
11.6 RXi Pharmaceuticals
11.6.1 RXi Pharmaceuticals Company Information
11.6.2 RXi Pharmaceuticals RNAi Therapeutics Product Offered
11.6.3 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 RXi Pharmaceuticals Main Business Overview
11.6.5 RXi Pharmaceuticals Latest Developments
11.7 Arrakis Therapeutics
11.7.1 Arrakis Therapeutics Company Information
11.7.2 Arrakis Therapeutics RNAi Therapeutics Product Offered
11.7.3 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Arrakis Therapeutics Main Business Overview
11.7.5 Arrakis Therapeutics Latest Developments
11.8 miRagen Therapeutics
11.8.1 miRagen Therapeutics Company Information
11.8.2 miRagen Therapeutics RNAi Therapeutics Product Offered
11.8.3 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 miRagen Therapeutics Main Business Overview
11.8.5 miRagen Therapeutics Latest Developments
11.9 Sylentis
11.9.1 Sylentis Company Information
11.9.2 Sylentis RNAi Therapeutics Product Offered
11.9.3 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Sylentis Main Business Overview
11.9.5 Sylentis Latest Developments
11.10 Gradalis
11.10.1 Gradalis Company Information
11.10.2 Gradalis RNAi Therapeutics Product Offered
11.10.3 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Gradalis Main Business Overview
11.10.5 Gradalis Latest Developments
11.11 Sirnaomics
11.11.1 Sirnaomics Company Information
11.11.2 Sirnaomics RNAi Therapeutics Product Offered
11.11.3 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Sirnaomics Main Business Overview
11.11.5 Sirnaomics Latest Developments
11.12 Silenseed
11.12.1 Silenseed Company Information
11.12.2 Silenseed RNAi Therapeutics Product Offered
11.12.3 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Silenseed Main Business Overview
11.12.5 Silenseed Latest Developments
11.13 Silexion Therapeutics
11.13.1 Silexion Therapeutics Company Information
11.13.2 Silexion Therapeutics RNAi Therapeutics Product Offered
11.13.3 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Silexion Therapeutics Main Business Overview
11.13.5 Silexion Therapeutics Latest Developments
11.14 Novartis
11.14.1 Novartis Company Information
11.14.2 Novartis RNAi Therapeutics Product Offered
11.14.3 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Novartis Main Business Overview
11.14.5 Novartis Latest Developments
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Information
11.15.2 Novo Nordisk RNAi Therapeutics Product Offered
11.15.3 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Novo Nordisk Main Business Overview
11.15.5 Novo Nordisk Latest Developments
11.16 Roche
11.16.1 Roche Company Information
11.16.2 Roche RNAi Therapeutics Product Offered
11.16.3 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Roche Main Business Overview
11.16.5 Roche Latest Developments
11.17 Sanofi
11.17.1 Sanofi Company Information
11.17.2 Sanofi RNAi Therapeutics Product Offered
11.17.3 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sanofi Main Business Overview
11.17.5 Sanofi Latest Developments
11.18 Regeneron Pharmaceuticals
11.18.1 Regeneron Pharmaceuticals Company Information
11.18.2 Regeneron Pharmaceuticals RNAi Therapeutics Product Offered
11.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Regeneron Pharmaceuticals Main Business Overview
11.18.5 Regeneron Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNAi Therapeutics Market Size (2021-2032)
2.1.2 RNAi Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNAi Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 RNAi Therapeutics Segment by Type
2.2.1 Subcutaneous Injection
2.2.2 Intravenous Infusion
2.2.3 RNAi Therapeutics Market Size by Type
2.2.3.1 RNAi Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global RNAi Therapeutics Market Size Market Share by Type (2021-2026)
2.3 RNAi Therapeutics Segment by Molecular Modality
2.3.1 Synthetic siRNA
2.3.2 shRNA / ddRNAi
2.3.3 miRNA Mimics / Inhibitors
2.3.4 bi-shRNA / bifunctional RNAi
2.3.5 Self-delivering RNAi
2.3.6 RNAi Therapeutics Market Size by Molecular Modality
2.3.6.1 RNAi Therapeutics Market Size CAGR by Molecular Modality (2021 VS 2025 VS 2032)
2.3.6.2 Global RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2026)
2.4 RNAi Therapeutics Segment by Business Model
2.4.1 Fully Integrated Biopharma
2.4.2 Platform-driven Licensing Model
2.4.3 Co-development / Profit-sharing Model
2.4.4 Others
2.4.5 RNAi Therapeutics Market Size by Business Model
2.4.5.1 RNAi Therapeutics Market Size CAGR by Business Model (2021 VS 2025 VS 2032)
2.4.5.2 Global RNAi Therapeutics Market Size Market Share by Business Model (2021-2026)
2.5 RNAi Therapeutics Segment by Application
2.5.1 Cardiovascular Disease
2.5.2 Genetic Disorder
2.5.3 Cancer
2.5.4 Other
2.5.5 RNAi Therapeutics Market Size by Application
2.5.5.1 RNAi Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global RNAi Therapeutics Market Size Market Share by Application (2021-2026)
3 RNAI THERAPEUTICS MARKET SIZE BY PLAYER
3.1 RNAi Therapeutics Market Size Market Share by Player
3.1.1 Global RNAi Therapeutics Revenue by Player (2021-2026)
3.1.2 Global RNAi Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global RNAi Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNAI THERAPEUTICS BY REGION
4.1 RNAi Therapeutics Market Size by Region (2021-2026)
4.2 Global RNAi Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNAi Therapeutics Market Size Growth (2021-2026)
4.4 APAC RNAi Therapeutics Market Size Growth (2021-2026)
4.5 Europe RNAi Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa RNAi Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNAi Therapeutics Market Size by Country (2021-2026)
5.2 Americas RNAi Therapeutics Market Size by Type (2021-2026)
5.3 Americas RNAi Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNAi Therapeutics Market Size by Region (2021-2026)
6.2 APAC RNAi Therapeutics Market Size by Type (2021-2026)
6.3 APAC RNAi Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNAi Therapeutics Market Size by Country (2021-2026)
7.2 Europe RNAi Therapeutics Market Size by Type (2021-2026)
7.3 Europe RNAi Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNAi Therapeutics by Region (2021-2026)
8.2 Middle East & Africa RNAi Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa RNAi Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNAI THERAPEUTICS MARKET FORECAST
10.1 Global RNAi Therapeutics Forecast by Region (2027-2032)
10.1.1 Global RNAi Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas RNAi Therapeutics Forecast
10.1.3 APAC RNAi Therapeutics Forecast
10.1.4 Europe RNAi Therapeutics Forecast
10.1.5 Middle East & Africa RNAi Therapeutics Forecast
10.2 Americas RNAi Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market RNAi Therapeutics Forecast
10.2.2 Canada Market RNAi Therapeutics Forecast
10.2.3 Mexico Market RNAi Therapeutics Forecast
10.2.4 Brazil Market RNAi Therapeutics Forecast
10.3 APAC RNAi Therapeutics Forecast by Region (2027-2032)
10.3.1 China RNAi Therapeutics Market Forecast
10.3.2 Japan Market RNAi Therapeutics Forecast
10.3.3 Korea Market RNAi Therapeutics Forecast
10.3.4 Southeast Asia Market RNAi Therapeutics Forecast
10.3.5 India Market RNAi Therapeutics Forecast
10.3.6 Australia Market RNAi Therapeutics Forecast
10.4 Europe RNAi Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market RNAi Therapeutics Forecast
10.4.2 France Market RNAi Therapeutics Forecast
10.4.3 UK Market RNAi Therapeutics Forecast
10.4.4 Italy Market RNAi Therapeutics Forecast
10.4.5 Russia Market RNAi Therapeutics Forecast
10.5 Middle East & Africa RNAi Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market RNAi Therapeutics Forecast
10.5.2 South Africa Market RNAi Therapeutics Forecast
10.5.3 Israel Market RNAi Therapeutics Forecast
10.5.4 Turkey Market RNAi Therapeutics Forecast
10.6 Global RNAi Therapeutics Forecast by Type (2027-2032)
10.7 Global RNAi Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNAi Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Information
11.1.2 Alnylam Pharmaceuticals RNAi Therapeutics Product Offered
11.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Alnylam Pharmaceuticals Main Business Overview
11.1.5 Alnylam Pharmaceuticals Latest Developments
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Company Information
11.2.2 Arrowhead Pharmaceuticals RNAi Therapeutics Product Offered
11.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Arrowhead Pharmaceuticals Main Business Overview
11.2.5 Arrowhead Pharmaceuticals Latest Developments
11.3 Silence Therapeutics
11.3.1 Silence Therapeutics Company Information
11.3.2 Silence Therapeutics RNAi Therapeutics Product Offered
11.3.3 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Silence Therapeutics Main Business Overview
11.3.5 Silence Therapeutics Latest Developments
11.4 Benitec Biopharma
11.4.1 Benitec Biopharma Company Information
11.4.2 Benitec Biopharma RNAi Therapeutics Product Offered
11.4.3 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Benitec Biopharma Main Business Overview
11.4.5 Benitec Biopharma Latest Developments
11.5 Phio Pharmaceuticals
11.5.1 Phio Pharmaceuticals Company Information
11.5.2 Phio Pharmaceuticals RNAi Therapeutics Product Offered
11.5.3 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Phio Pharmaceuticals Main Business Overview
11.5.5 Phio Pharmaceuticals Latest Developments
11.6 RXi Pharmaceuticals
11.6.1 RXi Pharmaceuticals Company Information
11.6.2 RXi Pharmaceuticals RNAi Therapeutics Product Offered
11.6.3 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 RXi Pharmaceuticals Main Business Overview
11.6.5 RXi Pharmaceuticals Latest Developments
11.7 Arrakis Therapeutics
11.7.1 Arrakis Therapeutics Company Information
11.7.2 Arrakis Therapeutics RNAi Therapeutics Product Offered
11.7.3 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Arrakis Therapeutics Main Business Overview
11.7.5 Arrakis Therapeutics Latest Developments
11.8 miRagen Therapeutics
11.8.1 miRagen Therapeutics Company Information
11.8.2 miRagen Therapeutics RNAi Therapeutics Product Offered
11.8.3 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 miRagen Therapeutics Main Business Overview
11.8.5 miRagen Therapeutics Latest Developments
11.9 Sylentis
11.9.1 Sylentis Company Information
11.9.2 Sylentis RNAi Therapeutics Product Offered
11.9.3 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Sylentis Main Business Overview
11.9.5 Sylentis Latest Developments
11.10 Gradalis
11.10.1 Gradalis Company Information
11.10.2 Gradalis RNAi Therapeutics Product Offered
11.10.3 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Gradalis Main Business Overview
11.10.5 Gradalis Latest Developments
11.11 Sirnaomics
11.11.1 Sirnaomics Company Information
11.11.2 Sirnaomics RNAi Therapeutics Product Offered
11.11.3 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Sirnaomics Main Business Overview
11.11.5 Sirnaomics Latest Developments
11.12 Silenseed
11.12.1 Silenseed Company Information
11.12.2 Silenseed RNAi Therapeutics Product Offered
11.12.3 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Silenseed Main Business Overview
11.12.5 Silenseed Latest Developments
11.13 Silexion Therapeutics
11.13.1 Silexion Therapeutics Company Information
11.13.2 Silexion Therapeutics RNAi Therapeutics Product Offered
11.13.3 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Silexion Therapeutics Main Business Overview
11.13.5 Silexion Therapeutics Latest Developments
11.14 Novartis
11.14.1 Novartis Company Information
11.14.2 Novartis RNAi Therapeutics Product Offered
11.14.3 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Novartis Main Business Overview
11.14.5 Novartis Latest Developments
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Information
11.15.2 Novo Nordisk RNAi Therapeutics Product Offered
11.15.3 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Novo Nordisk Main Business Overview
11.15.5 Novo Nordisk Latest Developments
11.16 Roche
11.16.1 Roche Company Information
11.16.2 Roche RNAi Therapeutics Product Offered
11.16.3 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Roche Main Business Overview
11.16.5 Roche Latest Developments
11.17 Sanofi
11.17.1 Sanofi Company Information
11.17.2 Sanofi RNAi Therapeutics Product Offered
11.17.3 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sanofi Main Business Overview
11.17.5 Sanofi Latest Developments
11.18 Regeneron Pharmaceuticals
11.18.1 Regeneron Pharmaceuticals Company Information
11.18.2 Regeneron Pharmaceuticals RNAi Therapeutics Product Offered
11.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Regeneron Pharmaceuticals Main Business Overview
11.18.5 Regeneron Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNAi Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNAi Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Subcutaneous Injection
Table 4. Major Players of Intravenous Infusion
Table 5. RNAi Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 7. Global RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Synthetic siRNA
Table 9. Major Players of shRNA / ddRNAi
Table 10. Major Players of miRNA Mimics / Inhibitors
Table 11. Major Players of bi-shRNA / bifunctional RNAi
Table 12. Major Players of Self-delivering RNAi
Table 13. RNAi Therapeutics Market Size CAGR by Molecular Modality (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global RNAi Therapeutics Market Size by Molecular Modality (2021-2026) & ($ millions)
Table 15. Global RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2026)
Table 16. Major Players of Fully Integrated Biopharma
Table 17. Major Players of Platform-driven Licensing Model
Table 18. Major Players of Co-development / Profit-sharing Model
Table 19. Major Players of Others
Table 20. RNAi Therapeutics Market Size CAGR by Business Model (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global RNAi Therapeutics Market Size by Business Model (2021-2026) & ($ millions)
Table 22. Global RNAi Therapeutics Market Size Market Share by Business Model (2021-2026)
Table 23. RNAi Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Table 26. Global RNAi Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global RNAi Therapeutics Revenue Market Share by Player (2021-2026)
Table 28. RNAi Therapeutics Key Players Head office and Products Offered
Table 29. RNAi Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Table 34. Global RNAi Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global RNAi Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas RNAi Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas RNAi Therapeutics Market Size Market Share by Country (2021-2026)
Table 38. Americas RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Table 40. Americas RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Table 42. APAC RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Table 44. APAC RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe RNAi Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe RNAi Therapeutics Market Size Market Share by Country (2021-2026)
Table 48. Europe RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of RNAi Therapeutics
Table 54. Key Market Challenges & Risks of RNAi Therapeutics
Table 55. Key Industry Trends of RNAi Therapeutics
Table 56. Global RNAi Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global RNAi Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global RNAi Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global RNAi Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Alnylam Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 61. Alnylam Pharmaceuticals RNAi Therapeutics Product Offered
Table 62. Alnylam Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Alnylam Pharmaceuticals Main Business
Table 64. Alnylam Pharmaceuticals Latest Developments
Table 65. Arrowhead Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 66. Arrowhead Pharmaceuticals RNAi Therapeutics Product Offered
Table 67. Arrowhead Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Arrowhead Pharmaceuticals Main Business
Table 69. Arrowhead Pharmaceuticals Latest Developments
Table 70. Silence Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 71. Silence Therapeutics RNAi Therapeutics Product Offered
Table 72. Silence Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Silence Therapeutics Main Business
Table 74. Silence Therapeutics Latest Developments
Table 75. Benitec Biopharma Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 76. Benitec Biopharma RNAi Therapeutics Product Offered
Table 77. Benitec Biopharma RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Benitec Biopharma Main Business
Table 79. Benitec Biopharma Latest Developments
Table 80. Phio Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 81. Phio Pharmaceuticals RNAi Therapeutics Product Offered
Table 82. Phio Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Phio Pharmaceuticals Main Business
Table 84. Phio Pharmaceuticals Latest Developments
Table 85. RXi Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 86. RXi Pharmaceuticals RNAi Therapeutics Product Offered
Table 87. RXi Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. RXi Pharmaceuticals Main Business
Table 89. RXi Pharmaceuticals Latest Developments
Table 90. Arrakis Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 91. Arrakis Therapeutics RNAi Therapeutics Product Offered
Table 92. Arrakis Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Arrakis Therapeutics Main Business
Table 94. Arrakis Therapeutics Latest Developments
Table 95. miRagen Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 96. miRagen Therapeutics RNAi Therapeutics Product Offered
Table 97. miRagen Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. miRagen Therapeutics Main Business
Table 99. miRagen Therapeutics Latest Developments
Table 100. Sylentis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 101. Sylentis RNAi Therapeutics Product Offered
Table 102. Sylentis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Sylentis Main Business
Table 104. Sylentis Latest Developments
Table 105. Gradalis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 106. Gradalis RNAi Therapeutics Product Offered
Table 107. Gradalis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Gradalis Main Business
Table 109. Gradalis Latest Developments
Table 110. Sirnaomics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 111. Sirnaomics RNAi Therapeutics Product Offered
Table 112. Sirnaomics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Sirnaomics Main Business
Table 114. Sirnaomics Latest Developments
Table 115. Silenseed Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 116. Silenseed RNAi Therapeutics Product Offered
Table 117. Silenseed RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Silenseed Main Business
Table 119. Silenseed Latest Developments
Table 120. Silexion Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 121. Silexion Therapeutics RNAi Therapeutics Product Offered
Table 122. Silexion Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Silexion Therapeutics Main Business
Table 124. Silexion Therapeutics Latest Developments
Table 125. Novartis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 126. Novartis RNAi Therapeutics Product Offered
Table 127. Novartis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Novartis Main Business
Table 129. Novartis Latest Developments
Table 130. Novo Nordisk Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 131. Novo Nordisk RNAi Therapeutics Product Offered
Table 132. Novo Nordisk RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Novo Nordisk Main Business
Table 134. Novo Nordisk Latest Developments
Table 135. Roche Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 136. Roche RNAi Therapeutics Product Offered
Table 137. Roche RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Roche Main Business
Table 139. Roche Latest Developments
Table 140. Sanofi Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 141. Sanofi RNAi Therapeutics Product Offered
Table 142. Sanofi RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Sanofi Main Business
Table 144. Sanofi Latest Developments
Table 145. Regeneron Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 146. Regeneron Pharmaceuticals RNAi Therapeutics Product Offered
Table 147. Regeneron Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Regeneron Pharmaceuticals Main Business
Table 149. Regeneron Pharmaceuticals Latest Developments
Table 1. RNAi Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNAi Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Subcutaneous Injection
Table 4. Major Players of Intravenous Infusion
Table 5. RNAi Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 7. Global RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Synthetic siRNA
Table 9. Major Players of shRNA / ddRNAi
Table 10. Major Players of miRNA Mimics / Inhibitors
Table 11. Major Players of bi-shRNA / bifunctional RNAi
Table 12. Major Players of Self-delivering RNAi
Table 13. RNAi Therapeutics Market Size CAGR by Molecular Modality (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global RNAi Therapeutics Market Size by Molecular Modality (2021-2026) & ($ millions)
Table 15. Global RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2026)
Table 16. Major Players of Fully Integrated Biopharma
Table 17. Major Players of Platform-driven Licensing Model
Table 18. Major Players of Co-development / Profit-sharing Model
Table 19. Major Players of Others
Table 20. RNAi Therapeutics Market Size CAGR by Business Model (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global RNAi Therapeutics Market Size by Business Model (2021-2026) & ($ millions)
Table 22. Global RNAi Therapeutics Market Size Market Share by Business Model (2021-2026)
Table 23. RNAi Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Table 26. Global RNAi Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global RNAi Therapeutics Revenue Market Share by Player (2021-2026)
Table 28. RNAi Therapeutics Key Players Head office and Products Offered
Table 29. RNAi Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Table 34. Global RNAi Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global RNAi Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas RNAi Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas RNAi Therapeutics Market Size Market Share by Country (2021-2026)
Table 38. Americas RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Table 40. Americas RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Table 42. APAC RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Table 44. APAC RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe RNAi Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe RNAi Therapeutics Market Size Market Share by Country (2021-2026)
Table 48. Europe RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa RNAi Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa RNAi Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa RNAi Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of RNAi Therapeutics
Table 54. Key Market Challenges & Risks of RNAi Therapeutics
Table 55. Key Industry Trends of RNAi Therapeutics
Table 56. Global RNAi Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global RNAi Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global RNAi Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global RNAi Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Alnylam Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 61. Alnylam Pharmaceuticals RNAi Therapeutics Product Offered
Table 62. Alnylam Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Alnylam Pharmaceuticals Main Business
Table 64. Alnylam Pharmaceuticals Latest Developments
Table 65. Arrowhead Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 66. Arrowhead Pharmaceuticals RNAi Therapeutics Product Offered
Table 67. Arrowhead Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Arrowhead Pharmaceuticals Main Business
Table 69. Arrowhead Pharmaceuticals Latest Developments
Table 70. Silence Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 71. Silence Therapeutics RNAi Therapeutics Product Offered
Table 72. Silence Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Silence Therapeutics Main Business
Table 74. Silence Therapeutics Latest Developments
Table 75. Benitec Biopharma Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 76. Benitec Biopharma RNAi Therapeutics Product Offered
Table 77. Benitec Biopharma RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Benitec Biopharma Main Business
Table 79. Benitec Biopharma Latest Developments
Table 80. Phio Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 81. Phio Pharmaceuticals RNAi Therapeutics Product Offered
Table 82. Phio Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Phio Pharmaceuticals Main Business
Table 84. Phio Pharmaceuticals Latest Developments
Table 85. RXi Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 86. RXi Pharmaceuticals RNAi Therapeutics Product Offered
Table 87. RXi Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. RXi Pharmaceuticals Main Business
Table 89. RXi Pharmaceuticals Latest Developments
Table 90. Arrakis Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 91. Arrakis Therapeutics RNAi Therapeutics Product Offered
Table 92. Arrakis Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Arrakis Therapeutics Main Business
Table 94. Arrakis Therapeutics Latest Developments
Table 95. miRagen Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 96. miRagen Therapeutics RNAi Therapeutics Product Offered
Table 97. miRagen Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. miRagen Therapeutics Main Business
Table 99. miRagen Therapeutics Latest Developments
Table 100. Sylentis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 101. Sylentis RNAi Therapeutics Product Offered
Table 102. Sylentis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Sylentis Main Business
Table 104. Sylentis Latest Developments
Table 105. Gradalis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 106. Gradalis RNAi Therapeutics Product Offered
Table 107. Gradalis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Gradalis Main Business
Table 109. Gradalis Latest Developments
Table 110. Sirnaomics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 111. Sirnaomics RNAi Therapeutics Product Offered
Table 112. Sirnaomics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Sirnaomics Main Business
Table 114. Sirnaomics Latest Developments
Table 115. Silenseed Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 116. Silenseed RNAi Therapeutics Product Offered
Table 117. Silenseed RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Silenseed Main Business
Table 119. Silenseed Latest Developments
Table 120. Silexion Therapeutics Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 121. Silexion Therapeutics RNAi Therapeutics Product Offered
Table 122. Silexion Therapeutics RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Silexion Therapeutics Main Business
Table 124. Silexion Therapeutics Latest Developments
Table 125. Novartis Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 126. Novartis RNAi Therapeutics Product Offered
Table 127. Novartis RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Novartis Main Business
Table 129. Novartis Latest Developments
Table 130. Novo Nordisk Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 131. Novo Nordisk RNAi Therapeutics Product Offered
Table 132. Novo Nordisk RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Novo Nordisk Main Business
Table 134. Novo Nordisk Latest Developments
Table 135. Roche Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 136. Roche RNAi Therapeutics Product Offered
Table 137. Roche RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Roche Main Business
Table 139. Roche Latest Developments
Table 140. Sanofi Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 141. Sanofi RNAi Therapeutics Product Offered
Table 142. Sanofi RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Sanofi Main Business
Table 144. Sanofi Latest Developments
Table 145. Regeneron Pharmaceuticals Details, Company Type, RNAi Therapeutics Area Served and Its Competitors
Table 146. Regeneron Pharmaceuticals RNAi Therapeutics Product Offered
Table 147. Regeneron Pharmaceuticals RNAi Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Regeneron Pharmaceuticals Main Business
Table 149. Regeneron Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. RNAi Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNAi Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNAi Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNAi Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. RNAi Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNAi Therapeutics Market Size Market Share by Type in 2025
Figure 10. Global RNAi Therapeutics Market Size Market Share by Molecular Modality in 2025
Figure 11. Global RNAi Therapeutics Market Size Market Share by Business Model in 2025
Figure 12. RNAi Therapeutics in Cardiovascular Disease
Figure 13. Global RNAi Therapeutics Market: Cardiovascular Disease (2021-2026) & ($ millions)
Figure 14. RNAi Therapeutics in Genetic Disorder
Figure 15. Global RNAi Therapeutics Market: Genetic Disorder (2021-2026) & ($ millions)
Figure 16. RNAi Therapeutics in Cancer
Figure 17. Global RNAi Therapeutics Market: Cancer (2021-2026) & ($ millions)
Figure 18. RNAi Therapeutics in Other
Figure 19. Global RNAi Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 20. Global RNAi Therapeutics Market Size Market Share by Application in 2025
Figure 21. Global RNAi Therapeutics Revenue Market Share by Player in 2025
Figure 22. Global RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Figure 23. Americas RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 24. APAC RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 25. Europe RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 27. Americas RNAi Therapeutics Value Market Share by Country in 2025
Figure 28. United States RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC RNAi Therapeutics Market Size Market Share by Region in 2025
Figure 33. APAC RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 34. APAC RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 35. China RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 39. India RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe RNAi Therapeutics Market Size Market Share by Country in 2025
Figure 42. Europe RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 43. Europe RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 44. Germany RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. France RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 46. UK RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 52. Egypt RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. APAC RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Europe RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. United States RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Canada RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Mexico RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Brazil RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. China RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Japan RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Korea RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. India RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Australia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Germany RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. France RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. UK RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Italy RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Russia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Egypt RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 77. South Africa RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 78. Israel RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 79. Turkey RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 80. Global RNAi Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global RNAi Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 1. RNAi Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNAi Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNAi Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNAi Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. RNAi Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNAi Therapeutics Market Size Market Share by Type in 2025
Figure 10. Global RNAi Therapeutics Market Size Market Share by Molecular Modality in 2025
Figure 11. Global RNAi Therapeutics Market Size Market Share by Business Model in 2025
Figure 12. RNAi Therapeutics in Cardiovascular Disease
Figure 13. Global RNAi Therapeutics Market: Cardiovascular Disease (2021-2026) & ($ millions)
Figure 14. RNAi Therapeutics in Genetic Disorder
Figure 15. Global RNAi Therapeutics Market: Genetic Disorder (2021-2026) & ($ millions)
Figure 16. RNAi Therapeutics in Cancer
Figure 17. Global RNAi Therapeutics Market: Cancer (2021-2026) & ($ millions)
Figure 18. RNAi Therapeutics in Other
Figure 19. Global RNAi Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 20. Global RNAi Therapeutics Market Size Market Share by Application in 2025
Figure 21. Global RNAi Therapeutics Revenue Market Share by Player in 2025
Figure 22. Global RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Figure 23. Americas RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 24. APAC RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 25. Europe RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa RNAi Therapeutics Market Size 2021-2026 ($ millions)
Figure 27. Americas RNAi Therapeutics Value Market Share by Country in 2025
Figure 28. United States RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC RNAi Therapeutics Market Size Market Share by Region in 2025
Figure 33. APAC RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 34. APAC RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 35. China RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 39. India RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe RNAi Therapeutics Market Size Market Share by Country in 2025
Figure 42. Europe RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 43. Europe RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 44. Germany RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. France RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 46. UK RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa RNAi Therapeutics Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa RNAi Therapeutics Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa RNAi Therapeutics Market Size Market Share by Application (2021-2026)
Figure 52. Egypt RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries RNAi Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. APAC RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Europe RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. United States RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Canada RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Mexico RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Brazil RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. China RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Japan RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Korea RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. India RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Australia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Germany RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. France RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. UK RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Italy RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Russia RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Egypt RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 77. South Africa RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 78. Israel RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 79. Turkey RNAi Therapeutics Market Size 2027-2032 ($ millions)
Figure 80. Global RNAi Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global RNAi Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries RNAi Therapeutics Market Size 2027-2032 ($ millions)
